Compared with conventional pharmaceuticals, orphan drugs are typically developed for rare diseases affecting very small patient populations. As a result, they have unique characteristics in research and development, market launch, inventory management, and international distribution.

Many orphan drugs are not only high-cost therapies, but also involve cold-chain transportation, small-batch supply, strict temperature control, and complex cross-border compliance procedures.

Today, the global distribution of orphan drugs mainly relies on the following six core supply channels.

1. Manufacturer Direct Supply

In the field of high-value orphan drugs, manufacturer direct supply is a very common distribution model.

Many pharmaceutical companies do not fully release these medicines into the general retail market. Instead, they supply them directly to designated hospitals, major medical centers, specialty pharmacies, and national procurement institutions.

This model is largely driven by the unique characteristics of orphan drugs. Since many rare disease therapies involve limited patient populations, high treatment costs, and strict requirements for transportation timing and temperature control, pharmaceutical companies often need to manage inventory, cold-chain logistics, and overall supply processes directly.

This channel is generally more suitable for:

● Large hospitals

● Rare disease treatment centers

● Advanced specialty healthcare networks

● National healthcare procurement systems

For some gene therapies and ultra-high-value medicines, manufacturer direct supply has already become the primary distribution approach.

2. Authorized Specialty Distributors

Because the orphan drug market spans multiple countries while patient populations remain relatively small and scattered, many pharmaceutical companies do not establish local teams in every market.

As a result, authorized specialty distributors have gradually become key participants in global orphan drug distribution.

These distributors are typically responsible for regional specialty medicine imports, local supply coordination, and cold-chain transportation. In markets such as Southeast Asia, the Middle East, and Latin America, authorized distribution networks often determine whether orphan drugs can effectively enter local healthcare systems.

Compared with conventional pharmaceutical distribution, orphan drug supply relies more heavily on:

● Small-batch supply

● Multi-country coordination

● Time-sensitive logistics

As the global rare disease market continues to expand, Chinese pharmaceutical wholesaler DengYueMed has also begun participating in Asian and cross-border orphan drug supply networks, providing more flexible specialty pharmaceutical distribution support for regional markets.

This channel is generally more suitable for:

● Regional procurement companies

● Private hospitals

● Specialty pharmaceutical distributors

● International healthcare channel organizations

3. Specialty Pharmacy Networks

In European and North American markets, many orphan drugs are not distributed through traditional retail pharmacies, but instead managed through specialty pharmacy networks.

Compared with conventional pharmacies, specialty pharmacies are responsible not only for medicine delivery, but also for long-term patient follow-up, cold-chain distribution, and patient medication education.

This model is especially common in:

● Biologic therapies

● Long-term injectable medicines

● Chronic rare disease treatments

● High-cost specialty pharmaceuticals

For many rare diseases requiring long-term treatment, specialty pharmacies have become an important connection point between pharmaceutical companies, healthcare providers, and patients.

This channel is generally more suitable for:

● Patients requiring long-term medication

● Home-care settings

● Chronic rare disease management systems

In recent years, as the specialty pharmaceutical market continues to grow, specialty pharmacies have become increasingly important within the global orphan drug supply chain.

4. Special Patient Access Channels

Not all orphan drugs are launched globally at the same time. In many cases, medicines may already be approved in certain countries while patients in other regions still cannot access treatment through standard channels.

Under these circumstances, special patient access pathways have become an important supplementary solution.

This model is typically used when a medicine has not yet been approved in a patient’s country, but there is an urgent treatment need. Through physician applications and special import approvals, some patients are able to access innovative therapiesbefore full commercial launch.

For many rare disease areas, special patient access programs have become one of the key international pathways for obtaining orphan drugs.

This channel is generally more suitable for:

● Critically ill patients

● Unlaunched markets

● International medical coordination organizations

As global innovative drug development accelerates, cross-border demand for special access medicines continues to grow.

5. International Pharmaceutical Wholesale Networks

In recent years, international pharmaceutical wholesale networks have played an increasingly important role in orphan drug supply.

Because many orphan drugs have limited global inventory, significant regional supply differences, and frequent shortage risks, more healthcare institutions are relying on international procurement and cross-border sourcing capabilities.

International pharmaceutical wholesale networks typically involve:

● Multi-country procurement coordination

● Emergency sourcing

● International cold-chain transportation

● Documentation and compliance support

Compared with conventional pharmaceutical trade, orphan drug wholesale distribution relies more heavily on global channel resources, specialty pharmaceutical supply experience, and rapid response capabilities.

International pharmaceutical wholesalers, including DengYueMed, are helping improve specialty medicine accessibility in certain markets through cross-regional supply coordination and specialty pharmaceutical distribution networks.

This channel is generally more suitable for:

● Hospital procurement departments

● International distributors

● Specialty pharmaceutical distribution networks

● Emergency medicine procurement organizations

6. Regional Transit and Distribution Hubs

Regional transit hubs are becoming increasingly important within the global orphan drug supply system.

Because many orphan drugs require strict temperature control, efficient customs clearance, and stable international transportation timelines, certain regions have gradually developed into major global specialty pharmaceutical distribution hubs.

For example:

● Hong Kong

● Singapore

● The Netherlands

● Dubai

all play important roles in international specialty pharmaceutical circulation.

These regional hubs usually offer advanced cold-chain capabilities, bonded warehousing systems, and efficient international logistics networks, helping improve cross-border distribution efficiency while reducing transportation risks.

This channel is generally more suitable for:

● Asia-Pacific procurement networks

● Middle Eastern healthcare channels

● International logistics coordination organizations

As the global specialty pharmaceutical market continues to grow, the strategic importance of regional distribution hubs is also increasing.

What Challenges Does Global Orphan Drug Supply Still Face?

Although the global orphan drug supply system continues to mature, the industry still faces multiple challenges, including high cold-chain transportation costs, international regulatory differences, small-batch manufacturing limitations, and occasional drug shortages.

For high-value biologics and gene therapies in particular, supply chain stability has become one of the key factors affecting market access and treatment availability.

At the same time, global demand for rare disease treatment continues to grow, further driving the expansion of international orphan drug supply networks.

Future Trends in Global Orphan Drug Supply Networks

As innovative therapies continue to increase, orphan drug supply systems are expected to become more internationalized, specialized, and digitalized.

In the coming years, the industry may continue developing toward:

● More mature international specialty pharmaceutical distribution networks

● More advanced cold-chain logistics systems

● More efficient cross-border procurement coordination

● Expansion of regional supply networks in Asia

For the global rare disease market, supply channels are no longer simply a logistics issue — they are increasingly becoming critical infrastructure connecting innovative therapies with healthcare systems worldwide.